WHAT IS CLAIMED IS:

- 1. A method of inducing blood vessel formation in an animal, comprising:administering to said animal an effective amount of a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 2. The method of Claim 1 wherein said sphingosine kinase, or analogue, fragment, or derivative thereof is administered to said animal by administering to said animal a polynucleotide encoding sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 3. The method of Claim 2 wherein said polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof is administered to said animal by administering to said animal an expression vehicle including said polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 4. The method of Claim 3 wherein said expression vehicle further includes a polynucleotide encoding a protein selected from the group consisting of VEGF, FGF, IGF, angiopoietins, PD-EGF, TGF- β , HIF1- α , nitric oxide synthase, MCP-1, Interleukin-8, ephrins, NAP-2, ENA-78, GROW- α , and active fragments of tyrosyl-tRNA synthetase.
- 5. The method of Claim 3 wherein said expression vehicle is a viral vector.
- 6. The method of Claim 5 wherein said viral vector is an adenoviral vector.
- 7. The method of Claim 5 wherein said viral vector is a lentiviral vector.
- 8. The method of Claim 5 wherein said viral vector is a BIV vector.
- 9. The method of Claim 6 wherein said adenoviral vector is administered to said animal in an amount of from about 10⁷ plaque forming units to about 10¹² plaque forming units.
- 10. The method of Claim 9 wherein said adenoviral vector is administered to said animal in an amount of from about $5x10^8$ plaque forming units to about $2x10^{11}$ plaque forming units.
- 11. The method of Claim 7 wherein said lentiviral vector is administered to said animal in an amount of from about $5x10^5$ transducing units to about 10^{12} transducing units.
- 12. The method of Claim 11 wherein said lentivirus vector is administered to said animal in an amount of from about $5x10^5$ transducing units to about 10^{12} transducing units.

- 13. The method of Claim 8 wherein said lentiviral vector is administered to said animal in an amount of from about $5x10^5$ transducing units to about 10^{10} transducing units.
- 14. The method of Claim 13 wherein said adenoviral vector is administered to said animal in an amount of from about 5x10⁵ transducing units to about 10¹⁰ transducing units.
- 15. The method of Claim 1 wherein said animal is a mammal.
- 16. The method of Claim 15 wherein said mammal is a primate.
- 17. The method of Claim 16 wherein said primate is a human.
- 18. A viral vector including a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 19. The vector of Claim 18 wherein said viral vector further includes a polynucleotide encoding a protein selected from the group consisting of VEGF, FGF, IGF, angiopoietins, PD-EGF, TGF-β, HIF1-α, nitric oxide synthase, MCP-1, Interleukin-8, and ephrins.
- 20. The vector of Claim 18 wherein said vector is an adenoviral vector.
- 21. The vector of Claim 18 wherein said viral vector is a lentiviral vector.
- 22. The vector of Claim 18 wherein said viral vector is a BIV vector.
- 23. A method of expressing sphingosine kinase in an animal, comprising:
 - administering to said animal a polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 24. The method of Claim 23 wherein said polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof is administered to said animal by administering to said animal an expression vehicle including said polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 25. The method of Claim 24 wherein said expression vehicle is a viral vector.
- 26. The method of Claim 25 wherein said viral vector is an adenoviral vector.

- 27. The method of Claim 25 wherein said viral vector is a lentiviral vector.
- 28. The method of Claim 25 wherein said viral vector is a BIV vector.
- 29. A method for the prevention or the treatment of congestive heart failure in an animal comprising administering to said animal an effective amount of a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 30. A method for the prevention or the treatment of myocardial ischemia in an animal comprising administering to said animal an effective amount of a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 31. A method for the treatment of ischemia-reperfusion injury in an animal comprising administering to said animal an effective amount of a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 32. A method for the treatment of peripheral arterial diseases in an animal comprising administering to said animal an effective amount of a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 33. The method of Claim 29, 30, 31 or 32 wherein said sphingosine kinase, or analogue, fragment, or derivative thereof is administered to said animal by administering to said animal a polynucleotide encoding sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 34. The method of Claim 33 wherein said polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof is administered to said animal by administering to said animal an expression vehicle including said polynucleotide encoding a sphingosine kinase, or an analogue, fragment, or derivative thereof.
- 35. The method of Claim 34 wherein said expression vehicle further includes a polynucleotide encoding a protein selected from the group consisting of VEGF, FGF, IGF, angiopoietins, PD-EGF, TGF-β, HIF1-α, nitric oxide synthase, MCP-1, Interleukin-8, and ephrins.
- 36. The method of Claim 34 wherein said expression vehicle is a viral vector.
- 37. The method of Claim 36 wherein said viral vector is an adenoviral vector

- 38. The method of Claim 36 wherein said viral vector is a lentiviral vector.
- 39. The method of Claim 36 wherein said viral vector is a BIV vector.
- 40. The method of Claim 29, 30, 31 or 32 wherein said animal is a mammal.
- 41. The method of Claim 40 wherein said mammal is a primate.
- 42. The method of Claim 41 wherein said primate is a human.